Red decorative startup news graphic with logos of companies featured in story

University of Utah startups continue innovating and discovering solutions to today’s unmet needs. Here’s a roundup of some of the latest news out of these companies:

Partnership Between ARUP and Medicover Expands Access to Companion Diagnostic in the European Union

ARUP logo

A partnership between ARUP Laboratories and Medicover has made a new companion diagnostic, and thereby a new gene therapy, more accessible to patients in the European Union. 

ARUP Laboratories, in close collaboration with BioMarin Pharmaceutical Inc., developed AAV5 DetectCDx™, a companion diagnostic that aids in the selection of adult patients with severe hemophilia A who are eligible for treatment with ROCTAVIAN™ (valoctocogene roxaparvovec-rvox), a new gene therapy developed by BioMarin. To facilitate access to the test in Europe, BioMarin and ARUP have partnered with Medicover, which provides diagnostic and healthcare services in Europe, to perform the testing at one of their facilities located in Germany for all countries in Europe.

Read more about the partnership

PlumCare and Fabric Genomics Announce a Strategic Partnership to Integrate the Fabric AI Platform with PlumCare’s FirstSteps™ Newborn Genome Screening Program in Greece

Fabric Genomics logo

PlumCare RWE and Fabric Genomics have partnered to deliver the Fabric AI platform with the PlumCare RWE FirstSteps newborn genome screening program in Greece. The goal of FirstSteps, a population health initiative, is to be able to screen every newborn in Greece by whole genome sequencing within the next five years.

Learn more about Fabric Genomics's news

Sera Prognostics Announces Primary Endpoint Criteria Met in Pivotal PRIME Study Interim Look - Enrollment to Stop Due to Success

Sera Prognostics logo

Sera Prognostics Inc., The Pregnancy Company® (Nasdaq: SERA), focused on improving maternal and neonatal health by providing innovative pregnancy biomarker information to doctors and patients, announced that the Data Safety Monitoring Board (DSMB) overseeing its pivotal Prematurity Risk Assessment Combined with Clinical Interventions for Improved Neonatal OutcoMEs (PRIME) study recommended stopping enrollment due to efficacy, reporting that either of the co-primary endpoints met the stopping criteria for statistical significance at the pre-planned interim analysis. The Company has adopted the DSMB's recommendation and will stop PRIME study enrollment to focus on analyzing and reporting the available data..

Learn more about Sera Prognostics's news

Questions?

We support you and your innovation.

Wherever you are on your innovation journey, the Technology Licensing Office is your go-to source to connect you with the U’s innovation ecosystem.

Call 801.581.7792 or send us a message